Organon & Co | OGN - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Celltrion KRW 49.87B 20.22B 2025-12
Cspc Pharmaceutical CNY 7.57B 793.73M 2025-06
Deva Holding AS TRY 775.92M 574.67M 2023-09
Dianthus Therapeutics USD 627.67M 576.58M 2026-03
Divis Laboratories Ltd INR 4.15B 31.87B 2025-03
Gilead Sciences USD 7.56B 234M 2025-12
Glaxosmithkline GBP 3.3B 303M 2025-09
Kangmei Pharma CNY 1.18B 278M 2025-09
Knight Therapeutics CAD 76.45M 5.43M 2025-12
Laboratorios Farma EUR 46.11M 18.92M 2025-06
Malin Corporation EUR 62.1M 26.4M 2024-12
Medical Developments International AUD 17.84M 219K 2025-06
Merck USD 5.33B 9.24B 2026-03
Neuren Pharmaceuticals AUD 5.91M 2.76M 2025-06
Novartis USD 9.56B 2.9B 2025-09
Organigram Holdings CAD 7.58M 20.62M 2025-12
Organon & Co USD 1.12B 542M 2026-03
Pharma Mar EUR 48.86M 31.05M 2026-03
Qiagen NV USD 839M 516.58M 2025-12
Sartorius EUR 573.8M 32.4M 2026-03
Sino Biopharmaceutical CNY 3.38B 2.09B 2024-12
Tilray USD 264.83M 43.16M 2025-06
Zealand Pharma A/S 4.58B 1.4B 2025-12